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Results

Background

• Hematopoietic cell transplantation (HCT) is a potentially
curative procedure indicated for high-risk hematalogic
malignancies
• Graft-versus-host-disease (GVHD) is a major source for
non-relapse morbidity and mortality in allogenic HCT
recipients
• Lung GVHD presents as bronchiolitis obliterans syndrome
(BOS), a severe lung disease
• BOS is diagnosed by progressive small airways
obstruction in the absence of infection
• NIH criteria are very stringent and may miss early cases
• On the other hand, a more flexible set of criteria (BOS 0p),
which only requires a 10% fall in forced spirometry, has a
70% false positive rate due to the low prevalence of BOS
• Biomarkers that are associated with early BOS can
minimize false positives and hasten the diagnosis of BOS.
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Figure 3. The heatmaps pictured illustrate the same outcomes

from Figure 2. Abundance does not show a statistically significant
difference amongst most groups. The only exception is between
the control vs. pre-BOS where a notable depletion of the
microbiome is appreciated in the pre-BOS group. Conclusions
drawn from these small sample sizes should be interpreted with
caution.
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Methods
Study Design
• 1 year observational study of
biomarkers in HSCT Recipient with GVHD
• Planned accrual of new diagnoses of (50 planned)
• Lung GVHD (BOS) – 20 patients
• BOS 0p (subclinical decline) – 20 patients
• Expect 30% to actually have BOS based on
prior data (preBOS) Remaining would be false
positive
• cGVHD controls – 10 patients
Analysis of the Microbiome
The α-diversity, β-diversity, and abundance were assessed in
each group. Bacterial 16s RNA sequencing was utilized to
determine the taxa presented in the results.
• α-diversity compares a single specimen amongst two
groups of interest.
• β-diversity compares community composition amongst two
groups.

Hypothesis
The oral and gut microbiome will in patients with BOS
and preBOS will be distinct from those patients who
have transient or no lung impairment
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Figure 1. The following figures illustrate an insignificant statistical

difference in α-diversity & β-diversity in the oral microbiome.

A

B
C

Figure 2. Abundance across all groups is not statistically

significant. The only exception is between the control vs. pre-BOS
where a notable depletion of the microbiome is appreciated in the
pre-BOS group.

Figure 4. The following figures illustrate an insignificant statistical

difference in α-diversity & β-diversity in the gut microbiome.
Relative abundance is not statistically different; however, there is
a small difference in species composition between BOS & nonBOS cases.

• Depletion of the oral microbiome is associated
with diagnosis of BOS and preBOS, but α- and
β-diversity were not.
• Recent studies have found strong associations
between pre-HCT microbial depletion and postHCT fatal lung injury in children (Zinter et al,
Blood 2021)
• However, observational designs may
mischaracterize the causal direction between
inflammation and microbial depletion
• Inducing experimental inflammation does not
lead to short-term changes in abundance or
diversity in preclinical models (Pantaleon et al,
Ann ATS 2021)
• Future work from the complete cohort will
analyze subgroup effects, control for antibiotic
use, and correlate with nasopharyngeal
inflammation.
• A larger study is necessary to systematically
evaluate other microbial compartments beginning
at a common time point and to correlate the
kinetics of microbial depletion with the kinetics of
inflammatory changes
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